SEP 4·SEC EDGARLow
Adams Brian sold $744K of KYMR
Adams Brian (Chief Legal Officer) sold 6,371 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $116.83 ($115.55–$117.57, $0.74M total) across 3 trades on 2026-09-04.
StockNASDAQ · US · USDHealthcare · Biotechnology
$KYMR
Kymera Therapeutics, Inc.
alphai earnings readsecond quarter of 2026 · AUG 5Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateVerdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $KYMRvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 0
- Neutral
- 2
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $744K 3 txs
Adams Brian3× · $744K
10b5-1 share of filings0%
Top stories · $KYMRMore →
SEP 3·theglobeandmail.com
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)
RBC Capital's Brian Abrahams maintained a Hold rating on Kymera Therapeutics (KYMR) with a $112 price target, while LifeSci Capital's Patrick Dolezal initiated coverage on vTv Therapeutics (VTVT) with a Buy rating and $60 target. KYMR's consensus price target is $135.22, and VTVT's is $58.50.
SEP 1·investingnews.com
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Kymera Therapeutics (KYMR) announced presentations on KT-621, its oral STAT6 degrader, at ERS and EADV congresses. The company completed enrollment in the BROADEN2 Phase 2b trial for atopic dermatitis, with topline data expected by year-end 2026. Phase 3 trials are planned for mid-2027. The BREADTH Phase 2b asthma trial is ongoing, with data expected in late 2027.
KYMR sentiment & insider activity
Over the past 7 days, alphai's AI scored 2 news stories mentioning KYMR (Kymera Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent KYMR coverage spans earnings, financial news and technology.
In the last 30 days, KYMR insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($744K). The most active reporter was Adams Brian, Chief Legal Officer, with 3 filings.
What's driving KYMR
Insider sale may signal lack of confidence, could pressure stock.
Analyst rating and target change may influence short‑term price action.
Positive trial progress may lift sentiment and attract speculative buying ahead of data release.
The call provides fresh, decision-relevant runway and accelerated/updated clinical milestones that can re-rate probability-weighted Phase III timelines.
The accelerated KT-621 AD enrollment and pulled topline timeline are a near-term catalyst for KYMR’s clinical execution narrative and risk profile.
alphai scores every news story that mentions KYMR with an AI model for sentiment and relevance, and aggregates insider trades from Kymera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $KYMR
Score
Adams Brian sold $744K of KYMR
Adams Brian (Chief Legal Officer) sold 6,371 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $116.83 ($115.55–$117.57, $0.74M total) across 3 trades on 2026-09-04.
1 min read
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)
RBC Capital's Brian Abrahams maintained a Hold rating on Kymera Therapeutics (KYMR) with a $112 price target, while LifeSci Capital's Patrick Dolezal initiated coverage on vTv Therapeutics (VTVT) with a Buy rating and $60 target. KYMR's consensus price target is $135.22, and VTVT's is $58.50.
2 min read
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Kymera Therapeutics (KYMR) announced presentations on KT-621, its oral STAT6 degrader, at ERS and EADV congresses. The company completed enrollment in the BROADEN2 Phase 2b trial for atopic dermatitis, with topline data expected by year-end 2026. Phase 3 trials are planned for mid-2027. The BREADTH Phase 2b asthma trial is ongoing, with data expected in late 2027.
2 min read
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics (KYMR) reported Q2 2026 collaboration revenue of $65M, including a $45M Gilead option fee and $20M Sanofi milestone. Cash and investments were $1.5B as of June 30, 2026, runway into 2029. R&D rose to $119.5M. KT-621 AD Phase 3 initiation is mid-2027, and asthma data is late 2027.
7 min readKymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.
6 min readKymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning
Kymera Therapeutics (KYMR) shares rose about 1% to $105.48 after Q2 results. The company reported collaboration revenue of $65.0m versus $11.5m a year earlier, with net loss of $61.2m (vs $76.6m) and trailing 12-month net loss of $299.6m. Management said no further 2026 collaboration revenue is expected without new milestones.
6 min read
Kymera’s KT-621 atopic dermatitis trial closes enrollment six months early
Kymera Therapeutics said its Phase 2b BROADEN2 trial of KT-621, an oral STAT6 degrader for atopic dermatitis, closed enrollment about six months early, moving topline results from mid-2027 to year-end 2026 and compressing Phase 3 start to mid-2027. The company cited Phase 1 data showing up to 98% STAT6 degradation in peripheral blood.
5 min readKymera Reports Narrower Loss In Q2 As Collaboration Revenue Jumps
Kymera Therapeutics (KYMR) reported Q2 net loss of $61.21M, or $0.62/share, narrower than $76.61M, or $0.95/share a year earlier, mainly due to $65M collaboration revenue. The quarter included a $45M Gilead option fee and $20M Sanofi milestone. Cash totaled $1.5B at June 30, 2026.
4 min readKymera Therapeutics, Inc. (KYMR): Results of Operations and Financial Condition
Kymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 tr
6 min readWill Kymera (KYMR) New CMO Hire Quietly Reframe Its Immunology Execution Story?
Kymera Therapeutics appointed Terence Rooney, MD as Chief Medical Officer, replacing Jared Gollob, who will retire and advise through year-end, according to the company. The article links the hire to Kymera’s oral immunology program, KT 621, noting early completion of enrollment in Phase 2b BROADEN2 for atopic dermatitis and highlighting forecast revenue of $44.7M and earnings of $7.6M by 2029.
6 min read